Affordable Access

deepdyve-link
Publisher Website

Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations.

Authors
  • Deng, Dao-Xing1
  • Zhu, Hong-Hu1
  • Liu, Yan-Rong1
  • Chang, Ying-Jun1
  • Ruan, Guo-Rui1
  • Jia, Jin-Song1
  • Jiang, Hao1
  • Jiang, Qian1
  • Zhao, Xiao-Su1
  • Huang, Xiao-Jun1, 2
  • 1 Peking University People's Hospital, Peking University Institute of Hematology , Beijing , China. , (China)
  • 2 Peking-Tsinghua Center for Life Sciences , Beijing , China. , (China)
Type
Published Article
Journal
Leukemia & Lymphoma
Publisher
Informa UK (Taylor & Francis)
Publication Date
Sep 01, 2019
Volume
60
Issue
9
Pages
2181–2189
Identifiers
DOI: 10.1080/10428194.2019.1576868
PMID: 30773106
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Acute myeloid leukemia (AML) patients with biallelic CEBPA (bi CEBPA) mutations are considered prognostically favorable, but 38-58% of them still relapse. Therefore, recognizing patients with a high risk of relapse is important. We retrospectively analyzed 83 bi CEBPA AML. Minimal residual disease (MRD) was detected by multiparameter flow cytometry (MFC). Patients with MRD positivity during consolidation chemotherapy had inferior 3-year CIR (55% vs. 36.7%; p = .037) and RFS (45% vs. 63.3%; p = .037) than those with MRD negativity. In patients with adverse cytogenetics, FLT3-ITD or MRD positivity, allogeneic hematopoietic stem cell transplantation (allo-HSCT) achieved superior 3-year CIR (0% vs. 52.8%; p = .006) and RFS (88.9% vs. 47.2%; p = .027) than did consolidation chemotherapy. Consolidation chemotherapy maintained a relatively favorable outcome (3-year CIR, 29%; 3-year RFS, 71%) in patients with intermediate cytogenetics, negative FLT3-ITD, and MRD negativity. Therefore, MFC-MRD could predict relapse and was complementary to genetics for risk stratification treatment in bi CEBPA AML.

Report this publication

Statistics

Seen <100 times